Skip to main content

Table 3 Baseline characteristics of adjuvant chemotherapy patients before and after PSM

From: Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

Characteristics

Before PSM (N = 939)

After PSM (N = 603)

PLD group (N = 292)

Epirubicin group (N = 647)

P value

PLD group (N = 201)

Epirubicin group (N = 402)

P value

Age (year), n (%)

  

0.0262

  

1.0000

  < 35

14 (4.8%)

58 (9.0%)

 

10 (5.0%)

20 (5.0%)

 

  ≥ 35

278 (95.2%)

589 (91.0%)

 

191 (95.0%)

382 (95.0%)

 

Age (year), Median (range)

48 (25,70)

49 (23,70)

0.8529

49 (42–56)

50 (44–56)

0.7495

Menopausal status, n (%)

  

0.2343

  

0.6739

 Premenopausal

115 (39.4%)

242 (37.4%)

 

105 (52.2%)

228 (56.7%)

 

 Postmenopausal

153 (52.4%)

384 (59.4%)

 

80 (39.8%)

161 (40.1%)

 

 Missing

24 (8.2%)

21 (3.3%)

 

16 (8.0%)

13 (3.2%)

 

Histological grade, n (%)

  

0.9289

  

0.4268

 I

3 (1.0%)

9 (1.4%)

 

2 (1.0%)

9 (2.2%)

 

 II

121 (41.4%)

294 (45.4%)

 

95 (47.3%)

206 (51.2%)

 

 III

77 (26.4%)

181 (28.0%)

 

52 (25.9%)

95 (23.6%)

 

 Missing

91 (31.2%)

163 (25.2%)

 

52 (25.9%)

92 (22.9%)

 

Nodal status, n (%)

  

0.0046

  

0.9049

 N0

141 (48.3%)

284 (43. 9%)

 

103 (51.2%)

202 (50.3%)

 

 N1

80 (27.4%)

184 (28.4%)

 

69 (34.3%)

202 (50.3%)

 

 N2

22 (7.5%)

89 (13.8%)

 

19 (9.5%)

36 (9.0%)

 

 N3

12 (4.1%)

58 (9.0%)

 

10 (5.0%)

26 (6.5%)

 

 Missing

37 (12.7%)

32 (5.0%)

 

0 (0.0%)

0 (0.0%)

 

Tumor size, n (%)

  

0.3915

  

0.4213

 T1

130 (44.5%)

268 (41.4%)

 

97 (48.3%)

182 (45.3%)

 

 T2

105 (36.0%)

277 (42.8%)

 

81 (40.3%)

179 (44.5%)

 

 T3

7 (2.4%)

16 (2.5%)

 

7 (3.5%)

8 (2.0%)

 

 T4

1 (0.3%)

5 (0.8%)

 

1 (0.5%)

1 (0.3%)

 

 Missing

49 (16.8%)

81 (12.5%)

 

15 (7.5%)

32 (8.0%)

 

Molecular subtype, n (%)

  

0.2054

  

0.7747

 Luminal A

56 (19.2%)

91 (14.1%)

 

40 (19.9%)

76 (18.9%)

 

 Luminal B

141 (48.3%)

317 (49.0%)

 

126 (62.7%)

261 (64.9%)

 

 HER2+

32 (11.0%)

76 (11.8%)

 

20 (10.0%)

43 (10.7%)

 

 BASAL-LIKE

17 (5.8%)

51 (7.9%)

 

15 (7.5%)

22 (5.5%)

 

 Missing

46 (15.8%)

112 (17.3%)

 

0 (0.0%)

0 (0.0%)

 

Ki-67 expression, n (%)

  

0.3344

  

0.2419

  < 20%

65 (22.3%)

122 (18.9%)

 

37 (18.4%)

93 (23.1%)

 

  ≥ 20%

174 (59.6%)

388 (60.0%)

 

125 (62.2%)

242 (60.2%)

 

 Missing

53 (18.2%)

137 (21.2%)

 

39 (19.4%)

67 (16.7%)

 
  1. PLD, pegylated liposomal doxorubicin